https://www.selleckchem.com/pr....oducts/santacruzamat
ly) and/or multiple neuroendocrine markers. This immunophenotypic spectrum may lead to diagnostic confusion with pulmonary adenocarcinoma, neuroendocrine tumour, and others. To circumvent this pitfall, NUT immunohistochemistry and/or NUTM1 molecular testing should be considered in primitive-appearing tumours, regardless of their immunophenotypic features.While immunotherapy has dramatically revolutionized the treatment of non-small cell lung cancer (NSCLC), it still faces challenges such as low therapeutic efficacy and
Like
Comment
Share
